NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=117013&from=3 CLASS PERIOD: May 10, 2024 to O ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 18, 2024 /PRNewswire/ ...

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=116392&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

Core Viewpoint - A class action securities lawsuit has been filed against Humacyte, Inc. due to alleged securities fraud affecting investors between May 10, 2024, and October 17, 2024 [1] Group 1: Allegations - The lawsuit claims that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, including quality assurance and microbial testing [2] - It is alleged that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies [2] - There is a substantial risk to the FDA approval of Humacyte's acellular tissue engineered vessel for vascular trauma as a result of these issues [2] - The defendants' positive statements regarding the company's business and prospects were misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 17, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]

NEW YORK, Dec. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=114728&from=4CLASS PERIOD: May 10, 2024 to October 17 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Humacyte, Inc. regarding a class action lawsuit due to alleged misleading statements and failures to disclose critical information during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 10, 2024, to October 17, 2024 [3]. - Allegations include that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, which included issues with quality assurance and microbial testing [3]. - It is claimed that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies, posing a substantial risk to FDA approval of their acellular tissue engineered vessel for vascular trauma [3]. - The lawsuit asserts that the defendants made materially misleading statements about the company's business, operations, and prospects, lacking a reasonable basis [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 17, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of Humacyte's stock [5].

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who purchased Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, alleging that the company misled investors regarding its manufacturing practices and the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel [1][2][3]. Group 1: Allegations and Impact - Humacyte is engaged in the development of Acellular Tissue Engineered Vessel (ATEV), a lab-grown blood vessel implant [2]. - On August 9, 2024, Humacyte announced that the FDA required additional time to review its BLA, leading to a stock price decline of $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [2]. - On October 17, 2024, the FDA issued a Form 483 revealing violations at Humacyte's Durham facility, including lack of microbial quality assurance and inadequate quality oversight, causing the stock price to drop by $0.95, or 16.35%, to close at $4.86 per share [2][3]. Group 2: Disclosure Failures - The complaint alleges that Humacyte failed to disclose that its Durham facility did not comply with good manufacturing practices, which included quality assurance and microbial testing [3]. - It is claimed that the company did not inform investors that the FDA's review of the BLA would be delayed due to the need for remediation of these deficiencies [3]. - The allegations suggest that there was a substantial risk to the FDA approval of ATEV for vascular trauma as a result of these undisclosed issues [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by January 17, 2025 [4]. - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Humacyte, Inc. due to alleged violations of federal securities laws, encouraging affected investors to seek legal recourse [2][4]. Group 1: Legal Investigation and Claims - The law firm is looking into claims against Humacyte, reminding investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that Humacyte and its executives made false or misleading statements regarding the company's compliance with manufacturing practices and the FDA's review process [4]. Group 2: Stock Price Impact - Following a press release on August 9, 2024, regarding delays in the FDA's review of Humacyte's Biologic License Application (BLA), the company's stock price fell by $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [5]. - On October 17, 2024, after the FDA released a Form 483 detailing violations at Humacyte's manufacturing facility, the stock price dropped by $0.95, or 16.35%, closing at $4.86 per share on the same day [6]. Group 3: Manufacturing Violations - The FDA's Form 483 indicated significant violations at Humacyte's Durham, North Carolina facility, including lack of microbial quality assurance and inadequate quality oversight [6]. Group 4: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Humacyte's conduct, including whistleblowers and former employees, to contact the firm [7].

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period”). Investors have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Cli ...

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=113435&from=3 CLASS PERIOD: May 10, 2024 to O ...